Prospects for the use of viral proteins for the construction of chimeric toxins
- PMID: 39327316
- DOI: 10.1007/s00705-024-06139-8
Prospects for the use of viral proteins for the construction of chimeric toxins
Abstract
One of the actively developing areas of drug development is the creation of chimeric toxins, recombinant bifunctional molecules designed to affect target cells selectively. The prevalent approach involves fusing bacterial and plant toxins with molecules that facilitate targeted delivery. However, the therapeutic use of such toxins often encounters challenges associated with negative side effects. Concurrently, viruses encode proteins possessing toxin-like properties, exerting multiple effects on the vital activity of cells. In contrast to bacterial and plant toxins, the impact of viral proteins is typically milder, presenting a significant advantage by potentially reducing the likelihood of side effects. This review delineates the characteristics of extensively studied viral proteins with toxic and immunomodulatory properties and explores the prospects of incorporating them into chimeric toxins.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
Construction of tumor-specific toxins using ubiquitin fusion technique.Mol Ther. 2005 Feb;11(2):196-204. doi: 10.1016/j.ymthe.2004.10.009. Mol Ther. 2005. PMID: 15668131
-
Apoptosis-inducing human-origin Fcepsilon-Bak chimeric proteins for targeted elimination of mast cells and basophils: a new approach for allergy treatment.J Immunol. 2001 Oct 15;167(8):4719-28. doi: 10.4049/jimmunol.167.8.4719. J Immunol. 2001. PMID: 11591803
-
[Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].Bull Cancer. 1997 Dec;84(12):1135-40. Bull Cancer. 1997. PMID: 9587366 Review. French.
-
Cytotoxic activity of ribonucleolytic toxin restrictocin-based chimeric toxins targeted to epidermal growth factor receptor.FEBS Lett. 1997 May 5;407(3):275-9. doi: 10.1016/s0014-5793(97)00333-5. FEBS Lett. 1997. PMID: 9175867
-
Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.Expert Opin Drug Deliv. 2011 May;8(5):605-21. doi: 10.1517/17425247.2011.566269. Epub 2011 Apr 1. Expert Opin Drug Deliv. 2011. PMID: 21453191 Review.
References
-
- Khoshnood S, Fathizadeh H, Neamati F et al (2022) Bacteria-derived chimeric toxins as potential anticancer agents. Front Oncol 12:953678. https://doi.org/10.3389/fonc.2022.953678 - DOI - PubMed - PMC
-
- Heiat M, Hashemi Yeganeh H, Alavian SM, Rezaie E (2021) Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect. Toxins 13:719. https://doi.org/10.3390/toxins13100719 - DOI - PubMed - PMC
-
- Antignani A, Fitzgerald D (2013) Immunotoxins: the role of the toxin. Toxins 5:1486–1502. https://doi.org/10.3390/toxins5081486 - DOI - PubMed - PMC
-
- Dunn RD, Weston KM, Longhurst TJ et al (1996) Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin. Immunotechnology Int J Immunol Eng 2:229–240. https://doi.org/10.1016/s1380-2933(96)00055-3 - DOI
-
- Choo ABH, Dunn RD, Broady KW, Raison RL (2002) Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expr Purif 24:338–347. https://doi.org/10.1006/prep.2001.1589 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources